ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ESRX Express Scripts Holding Company (delisted)

92.33
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Express Scripts Holding Company (delisted) NASDAQ:ESRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 92.33 92.35 92.56 0 01:00:00

Anthem Signs Five-Year Deal With CVS for Services to New Pharmacy-Benefit Manager IngenioRx

18/10/2017 12:59pm

Dow Jones News


Express Scripts Holding Company (delisted) (NASDAQ:ESRX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Express Scripts Holding Company (delisted) Charts.
By Anna Wilde Mathews 

Anthem Inc. said it would launch its own pharmacy-benefit manager, serviced by CVS Health Corp., in 2020 after the conclusion of its current contract with Express Scripts Holding Co.

Anthem's move to create IngenioRx is a blow to Express Scripts, which is losing its biggest customer, but Express Scripts had warned in April that Anthem was unlikely to renew their 10-year pact once it expires at the end of 2019. Anthem has sued Express Scripts for allegedly overcharging on prescription drugs over several years.

Anthem's decision is a win for CVS, which gains even more heft with the addition of the script volume associated with the second-biggest U.S. insurer. UnitedHealth Group Inc.'s OptumRx, had been seen facing a challenge in winning Anthem's business because UnitedHealth's insurance arm is Anthem's direct competitor. Anthem said it had signed a five-year contract with CVS.

Anthem said IngenioRx will seek to sign up other clients, as well. Among others, Anthem may be targeting the business of its fellow Blue Cross Blue Shield insurers. For several years, insurers have generally been seeking to diversify their businesses, aiming to follow the model of UnitedHealth's success with its Optum health-services unit, of which OptumRx is a part.

Anthem's CEO, Joseph R. Swedish, said the insurer had "determined that our scale and experience best position us to deliver an innovative solution, and the launch of IngenioRx will allow us to break through what is now a complex and fragmented landscape." He said the move "also positions Anthem to take advantage of a unique opportunity to grow and diversify our business within our existing footprint as well as nationally."

Anthem's decision takes it back toward a setup it had before its contract with Express Scripts, which took over Anthem's pharmacy services in 2009 when it bought Anthem's in-house PBM for about $4.68 billion. Anthem didn't immediately disclose any financial details of its agreement with CVS.

Express Scripts just announced that it would buy private medical-benefits manager eviCore healthcare for $3.6 billion from investors TA Associates, Ridgemont Equity Partners and General Atlantic. Anthem's business had been worth around $17.1 billion in annual revenue to Express Scripts.

Anthem sued Express Scripts in 2016, seeking around $15 billion in damages and arguing that the PBM has overcharged it for drugs under their deal. Express has denied the allegations and made its own counterclaims.

Write to Anna Wilde Mathews at anna.mathews@wsj.com

 

(END) Dow Jones Newswires

October 18, 2017 07:44 ET (11:44 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1 Year Express Scripts Holding Company (delisted) Chart

1 Year Express Scripts Holding Company (delisted) Chart

1 Month Express Scripts Holding Company (delisted) Chart

1 Month Express Scripts Holding Company (delisted) Chart

Your Recent History

Delayed Upgrade Clock